Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Asahi Kasei Pharma Applies for Teriparatide in Japan
November 1, 2010
- Shionogi Begins PIII for Next-Generation Anti-HIV Drug
November 1, 2010
- NV1FGF Fails to Meet PIII Primary Endpoint
November 1, 2010
- Korosho Warns against Allergic Reactions to Hydrolyzed Wheat Powder
November 1, 2010
- Takeda Applies for Successor of Candesartan
November 1, 2010
- Takara Bio Begins Leukemia Gene Therapy in 1st Subject
November 1, 2010
- Iressa Fails to Extend OS in 1st Line Treatment for NSCLC
November 1, 2010
- Teijin's Gout Drug Launched in Canada
November 1, 2010
- FDA Rejects Eisai's Application for Lorcaserin
November 1, 2010
- Kowa to Present Peretinoin Data at AASLD 2010
November 1, 2010
- Number of Hub Medical Institutions for Clinical Trials Reduced to 20
November 1, 2010
- Astellas to Transfer Intal to sanofi-aventis
November 1, 2010
- Dabigatran Approved for SPAF in the US
November 1, 2010
- Cabazitaxel Improves Survival in Prostate Cancer Patients
November 1, 2010
- Astellas Licenses Dysuria Drug from ASKA
November 1, 2010
- MSD Launches Higher-Strength Asmanex
November 1, 2010
- BI's Combination Drug for Hypertension Receives EU Approval
November 1, 2010
- Afinitor plus Sandostatin Extended PFS in NET Patients: Novartis
November 1, 2010
- Shionogi Allies with Swedish Academia
November 1, 2010
- CDFS Subcommittee to Discuss Safety Measures for Mylotarg
November 1, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…